ADA Guidelines 2021
Standards of Medical Care in Diabetes

ADA announces new evidence-based guidelines and recommendations

A multidisciplinary expert committee including members of ADA updates the Standards of Care annually. The Standards of Medical Care in Diabetes 2021 – provides the latest in comprehensive, evidence based recommendations for the diagnosis and treatment of children & adults with type 1, type 2, or gestational diabetes; strategies for prevention or delay of type 2 diabetes; and therapeutic approaches that can reduce complications, mitigate cardiovascular (CV) and renal risk and improve health outcomes.

The current ADA guidelines included some of the key updates:
1. Evidence for diabetes treatment for people also managing chronic kidney disease (CKD) and heart failure.
2. The use of technology for diabetes management and individualized care as well as recommendations for continuous glucose monitoring (CGM) for people with diabetes.
3. Important information on addressing social determinants of health in diabetes.
4. Barriers to and critical times for diabetes self-management education and support (DSMES).
5. Vaccine-specific updates, including those related to COVID-19.

COVID-19 Corner: Care is better than Cure!

- The “Immunizations” subsection has been significantly revised. More information has been added to the discussion of each vaccine, including important considerations related to coronavirus disease 2019 (COVID-19).
- During the coming year it is expected that vaccines for COVID-19 will become available and people with diabetes would be a priority population. The COVID-19 vaccine will likely become a routine part of the annual preventive schedule for people with diabetes.

Diabetes Technology: The importance of CGM during pandemic and beyond

- New information added to diabetes technology section to consider CGM as useful tool for people with diabetes on multiple daily injections, continuous subcutaneous insulin infusions and other forms of insulin therapy regardless of age or diabetes type.
- The section provides advice on use of time in range data for glycemic monitoring, particularly during the COVID-19 pandemic when remote monitoring is preferable.
Patients must be advised to achieve and maintain 7% loss of initial body weight and increase moderate intensity physical activity (such as brisk walking) to at least 150 mins/week.

A variety of eating patterns like low-carbohydrate, Dietary Approaches to Stop Hypertension (DASH) are associated with lower risk of developing Type 2 Diabetes (T2DM).

Certified technology-assisted diabetes prevention programs may be effective in preventing T2DM and should be considered.

Metformin therapy for prevention of T2DM should be considered in those with prediabetes, especially for those with BMI ≥35 kg/m2, those aged <60 years, and women with prior gestational diabetes mellitus.

To know your risk of prediabetes click below-

Pharmacological Therapy for Type 1 Diabetes

Most people with type 1 diabetes should be treated with multiple daily injections of prandial and basal insulin, or continuous insulin infusion.

Most people with type 1 diabetes should use rapid-acting insulin analogs to reduce hypoglycemia risk.

Patients with type 1 diabetes should receive education on how to match prandial insulin doses to carbohydrate intake, pre-meal blood glucose and anticipated physical activity.

Pharmacological Therapy for Type 2 Diabetes (T2DM)

Metformin is the preferred initial pharmacological agent for the treatment of T2DM unless contraindicated.

Early combination therapy can be considered in some patients at treatment initiation to extend the time to treatment failure.

Combination Therapy: Initial combination therapy should be considered in patients presenting with A1C levels 1.5 - 2.0 % above target.

The VERIFY trial demonstrated that initial combination therapy (Metformin + Vildagliptin) is superior to sequential addition of medications for extending primary and secondary failure.

These results have not been generalized to DPP-4i other than Vildagliptin.

Other options for first line therapy: Sulfonylureas, Dipeptidyl peptidase 4 inhibitor (DPP-4i), Sodium-Glucose linked transporter 2 inhibitor (SGLT2i) or Alpha-glucosidase inhibitors, if Metformin not tolerated.

In patients with T2DM, a glucagon-like peptide 1 receptor agonist is preferred to Insulin when possible.

Algorithm for pharmacological management of T2DM was revised to include a dedicated decision pathway for CKD and a dedicated decision pathway for heart failure, with updates to reflect consensus interpretation of clinical trial data.

To know your ASCVD score, click below-
Glucose Lowering Medication in T2DM: A Patient-Centric Approach

**FIRST-LINE Therapy** is Metformin and Comprehensive Lifestyle (including weight management and physical activity).

If A1C above Individualized Target, Proceed as Below:

- **Compelling Need to Minimize Hypoglycemia**
  - DPP-4i
  - GLP-1 RA with good efficacy for weight loss
  - Metformin or SGLT2i

- **Compelling Need to Promote Weight Loss**
  - GLP-1 RA with good efficacy for weight loss
  - SGLT2i

- **Cost is a Major Issue**
  - SU
  - TZD

If further intensification is required or patient is unable to tolerate GLP-1 RA and/or SGLT2i, choose agents demonstrating CV benefit and/or safety:

- For patients on a GLP-1 RA, consider adding SGLT2i with proven CV benefit and/or safety:
  - TZD
  - DPP-4i if not on GLP-1 RA
  - Basal insulin

**For patients with T2D and CVD** (e.g., ≥26% 10-year mortality risk) and thus at increased risk of cardiovascular events:

- **SGLT2i**
- **TZD**

7. Proven benefit means it has label indication of reducing heart failure in this population.
8. Refer to Section 11: Microvascular Complications and Foot Care
9. DEX/NAglucose U-100 < glucose U-100 / dextrose + insulin
10. Drugs: > iraglutide > exenatide > exenatide + basal insulin
11. On specific comorbidities (e.g., established CVD), low risk of hypoglycemia, and lower priority to avoid weight gain or no weight-related comorbidities
12. Consider country- and region-specific cost of drugs. In some countries T2D are relatively more expensive and DPP-4i are relatively cheaper.

1. Acted as when these become new clinical indications regardless of background glucose-lowering medications.
2. Most patients enrolled in the relevant trials were on metformin at baseline as glucose-lowering therapy.
CVD Risk Management: Right steps to Reduce the Risk!

- For patients with blood pressure >120/80 mmHg, lifestyle intervention consists of weight loss when indicated, a DASH-style eating pattern including reducing sodium and increasing potassium intake, moderation of alcohol intake, and increased physical activity.

- For individuals with diabetes and hypertension at higher CV risk (existing ASCVD or 10-year ASCVD risk ≥15%), a blood pressure target of <130/80 mmHg may be appropriate, if it can be safely attained.

**Hypertension**

- ACE inhibitors or ARBs as first-line therapy for hypertension in people with diabetes and CAD.

**Recommendation:**

- Treatment for hypertension should include drug classes demonstrated to reduce CV events in patients with diabetes.

- ACE inhibitors or ARBs are recommended first-line therapy for hypertension in people with diabetes and CAD.

**Lipid management**

- The ODYSSEY OUTCOMES trial has been added to the “Combination Therapy for LDL Cholesterol Lowering” subsection.

- In ODYSSEY OUTCOMES trial, 18924 patients (~28% of whom had diabetes) with recent acute coronary syndrome (ACS) were randomized to receive PCS-K9 inhibitor Alirocumab or placebo every 2 weeks. Over a median follow up of 2.8 years, there was a significant 15% (p<0.001) reduction in the rate of composite end point (death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke or unstable angina requiring hospitalization) with Alirocumab versus placebo.

- Similar results were observed for Evolocumab in FOURIER Trial.

- In DAPA-HF trial SGLT2i, Dapagliflozin has demonstrated significant risk reduction in worsening of heart failure and CV death in patients with Heart Failure with reduced ejection fraction (HFrEF). The effect of Dapagliflozin was consistent regardless of the presence or absence of T2DM.

- EMPA-REG and CANVAS trials have demonstrated that Empagliflozin and Canagliflozin respectively showed significant risk reduction in composite outcome of MI, Stroke, and CV death.
Anti-platelet agents

- Recommendations were added to the “Antiplatelet Agents” subsection regarding long-term dual antiplatelet therapy and combination therapy with Aspirin plus low dose Rivaroxaban, respectively.

**Recommendation:**
- Dual antiplatelet therapy (DAPT) with low-dose Aspirin and a P2Y12 inhibitor is reasonable for a year after an ACS and may have benefits beyond this period.
- Long term treatment with DAPT should be considered for patients with prior coronary intervention, high ischemic risk, and low bleeding risk to prevent major adverse CV events.

Renal Risk Management: Healthy Kidney is Risk Free Kidney

- At least annually, urinary albumin (e.g., spot urinary albumin-to-creatinine ratio) and estimated glomerular filtration (eGFR) rate should be assessed in patients with type 1 diabetes with duration of ≥5 years and in all patients with T2DM regardless of treatment.
- In patients with T2DM and diabetic kidney disease, consider use of SGLT2 inhibitors additionally for CV risk reduction when eGFR and urinary albumin creatinine (UACR) are ≥30 mL/min/1.73 m² or >300 mg/g, respectively.
- In CREDENCE trial, Canagliflozin was shown to significantly reduce the development of End Stage Renal Disease (ESRD). Additionally, it also showed significant risk reduction in renal and CV death. This benefit was on background of ACE inhibitor or ARB therapy.
- In patients with CKD who are at increased risk for CV events, use of a glucagon-like peptide 1 receptor agonist reduces renal end point, primarily albuminuria, progression of albuminuria, and CV events.
- ACE inhibitors or ARBs are the preferred first-line agent for blood pressure treatment among patients with diabetes, hypertension, eGFR <60 mL/min/1.73 m², and UACR ≥300 mg/g Creatinine because of their proven benefits for prevention of CKD progression.
- SGLT2 inhibitors and GLP-1 RAs should be considered for patients with T2DM and CKD who require another drug added to Metformin to attain target A1C or cannot use or tolerate Metformin.

---

For any scientific queries on the above topic
Write to the Scientific Department at:

+91 8879607724 or scientific@aristopharma.org

For reporting any adverse drug reactions (ADRs) observed with the products of Aristo Pharmaceuticals Private Limited, contact: Email: aepvc.scientific@aristopharma.org or Toll-free No. 1800225960 (Monday to Friday between 9.30 am to 5.30 pm, except on public holidays) or WhatsApp: +918879607724.